X
<
COST-Stock-2-1
Costco Tops Fiscal 1Q18 Estimates

Costco Wholesale (COST) reported stronger-than-expected fiscal 1Q18 results, surpassing analysts’ expectations for both sales and EPS (earnings per share).

Asian
Pre-Market Report: Global Markets Are Weak on December 15

After a pullback on Thursday, the Shanghai Composite Index opened lower on December 15 and fell to five-week low price levels.

sp-500-1
US Markets Had a Mixed Performance on December 14

The S&P 500 started this week on a stronger note. Despite a strong start, the market lost momentum as the week progressed and fell on Thursday.

KSS-Price-1
Can Kohl’s Stock Pick Up Some Momentum?

Kohl’s (KSS) stock price has risen 1.8% on a YTD (year-to-date) basis as of December 12.

RECENT Healthcare RESEARCH

highlights
How Is Varian Positioned for 2018 after 2017 Transformation?

On November 30, 2017, Varian Medical Systems (VAR) was trading at its 52-week high of $111.40. On November 29, it ended trading at $111.20, its highest closing price for the last 52 weeks.

oprating-margin-1
Medtronic in 2018 and Beyond: Major Drivers and Headwinds

Medtronic (MDT) reported net adjusted profits of ~$1.5 billion for fiscal 2Q18, an ~7.0% year-over-year decline. This report included an ~3.0% negative impact resulting from Hurricane Maria.

Graph-1-5-1
Who's Watching Myriad Genetics in 2017?

Myriad Genetics reported fiscal 1Q18 revenues and adjusted EPS of ~$190 million and ~$0.26, respectively, surpassing the analyst estimates.

analyst-recommendations-5-1
The Latest on Baxter International: Developments, Sentiment

BAX stock reached its 52-week high on October 27, triggered by positive investor sentiment following its stellar quarterly performance and future outlook.

Bristol-revenues-1
How Did Bristol-Myers Squibb Perform in 3Q17?

In 3Q17, Bristol-Myers Squibb (BMY) reported revenues of $5.3 billion, a ~7% increase on a year-over-year (or YoY) basis and a 2% increase on a quarter-over-quarter basis.

4q17-highlights-1
BD Stock Reaches 52-Week High on November 27

BD released its 4Q17 and fiscal 2017 earnings results on November 2, 2017. That day, the stock rose ~7.7%, registering a record high thanks to the company’s stellar earnings results.

Pfizer-revenues-1
A Look at Pfizer's Key Drivers in 2017

In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

Graph-1-4-1
Should We Be Interested in Nektar Therapeutics in November 2017?

In 3Q17, Nektar Therapeutics (NKTR) reported revenues of $152.9 million, a YoY rise of 320.7%. The sudden spurt is mainly due to the upfront payment of $150 million from Eli Lilly.

Chart-001-Rev-1
Understanding Eli Lilly's Valuation after 3Q17

Eli Lilly (LLY) reported 9% YoY (year-over-year) growth in its top line to ~$5.7 billion for 3Q17.

HIGHLIGHTS
What Investors Should Know about Medtronic's Fiscal 2Q18 Earnings

Medtronic released its 2Q18 earnings results on November 21, 2017. The company registered sales of around $7.1 billion, representing a YoY (year-over-year) decline of around 4%.

Chart-01-3-1
What's Driving Johnson & Johnson’s Valuation?

As of November 21, 2017, Johnson & Johnson was trading at a forward PE multiple of ~17.6x as compared to the industry average of 16.2x.

analyst-recommendations-3-1
Can Abbott Laboratories Keep up the Growth Momentum?

Abbott registered strong 3Q17 results, surpassing estimates for both sales and earnings and reporting healthy growth across all of its business segments.

Teva
All Eyes on Teva Pharmaceuticals?

Teva (TEVA) reported 3Q17 revenues of $5.6 billion, which represents a ~1% YoY (year-over-year) rise but a 1% QoQ (quarter-over-quarter) fall.

Synergy-pharma-analysts-recommendations-1
Who's Excited about Synergy's Trulance This November?

According to Synergy, it’s estimated that ~33 million people suffer from CIC and 12 million people suffer from IBS-C in the US.

Graph-1-3-1
Who's Watching Exelixis in November 2017?

Exelixis (EXEL) reported total revenues of ~$152.5 million in 3Q17, which represented a YoY rise of ~145.2%, mainly due to rising demand for Cabometyx.

Merck-revenues-1
How Is Merck Positioned after 3Q17?

In 3Q17, Merck (MRK) reported revenue of $10.3 billion, which reflected a ~2% fall YoY (year-over-year) and ~4% growth QoQ (quarter-over-quarter).

medical-device-segment-performance-1
Inside JNJ's Medical Device Business: Developments, Future Growth

In 3Q17, Johnson & Johnson (JNJ) reported ~$19.7 billion in sales. The company’s Medical Devices business generated ~33.5% of the total sales.

Graph-1-2-1
Edwards LifeSciences: Here's What's Going On in November 2017

In 3Q17, Edwards Lifesciences (EW) reported adjusted sales of ~$838 million, which is an underlying growth of ~13% on a YoY basis. This performance was driven by double-digit organic growth.

Endo-analysts-ratings-1
Who's Watching Endo International in 2017?

Of the 21 analysts covering Endo in November 2017, six recommend a “buy” for the stock, while 14 recommend a “hold,” and one recommends a “sell.”

Chart-01-2-1
What's Driving AstraZeneca's Valuation after 3Q17 Results?

In 3Q17, AstraZeneca reported EPS of $0.56 on revenues of $6.2 billion compared to estimates of $0.71 for EPS on revenues of $6 billion.

X

Please select a profession that best describes you: